BioSpace News Archive

Zynex, Inc. announced today that it will host the Company’s 2021 second quarter earnings investor webcast on Thursday, July 29,2021 at 2:15 p.m. Mountain Time.

STAAR Surgical Company, a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, announced that it will release financial results for the second quarter ended July 2, 2021 on Wednesday, August 4, 2021 after the market close.

Pressure BioSciences, Inc. today announced it has established a wholly-owned agrochemicals subsidiary named PBI Agrochem, Inc.

Kazia Therapeutics Limited, a leading drug development company in the field of brain cancer, recognizes Glioblastoma Awareness Day and calls for a greater focus on research from industry, academia, and government in order to better treat the disease.

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today new data for valoctocogene roxaparvovec, an investigational gene therapy treatment for adults with severe hemophilia A, from its open-label Phase 1/2 study during an oral presentation at the International Society on Thrombosis and Haemostasis (ISTH) 2021 Virtual Congress.

RefleXion Medical, Inc., a therapeutic oncology company pioneering biology-guided radiotherapy* as a new modality that will one day treat all stages of cancer, announced the sale of its RefleXion™ X1 machine to The Center for Cancer and Blood Disorders, a free-standing cancer treatment center with 15 locations throughout northern Texas.

Venock is developing a vascular closure system for large bore punctures (up to 30 Fr and larger) in vessels following transvenous catheter-based therapies such as atrial ablations, leadless pacemaker implantations, ECMO, and various structural heart therapies such as Mitral- and Tricuspid- Valve Repair and Replacement.

Spark Therapeutics, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) and a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, today announced updated data from the ongoing Phase 1/2 clinical trial of investigational SPK-8011 in hemophilia A during the International Society of Thrombosis and Hemostasis (ISTH) 2021 Virtual Congress (July 17-21).

MB-204 is the Company’s lead compound with potential application to the neurological diseases of depression & anxiety, Alzheimer’s, ADHD and non-neurological diseases such as cancer and non-alcoholic steatohepatitis.

Prior to this appointment, Benjamin Krantz MD, MBA was the Chief Fellow in hematology/oncology at New York University Langone Medical Center and served on the Board of Directors of APTI.